PRTA -Prothena Corporation plc

Prothena Corporation plc

PRTA

$8.56

Name : Prothena Corporation plc

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $439,554,272.00

EPSttm : -0.45

Prothena Corporation plc

$8.56

2.45%

$0.215

PRTA — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

18.08

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

0.84

EPS Last/This Y

5.17

EPS This/Next Y

-1.96

Price

8.57

Target Price

21.4

Analyst Recom

Performance Q

-7.56

Upside

-171.4%

Beta

-0.22

Ticker: PRTA

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	PRTA	8.45	0.50	166.13	7950
2026-10-13	PRTA	8.36	0.44	0.00	7677
2026-10-14	PRTA	8.37	0.44	0.33	7687
2026-10-15	PRTA	8.51	0.44	0.00	7688
2026-10-16	PRTA	8.36	0.44	0.00	7689
2026-10-19	PRTA	8.48	0.45	0.00	7300
2026-10-20	PRTA	8.51	0.45	0.00	7307
2026-10-21	PRTA	8.05	0.38	0.00	8308
2026-10-22	PRTA	8.24	0.38	0.00	8249
2026-10-23	PRTA	8.2	0.38	0.00	8250
2026-10-26	PRTA	8.4	0.38	0.00	8250
2026-10-27	PRTA	8.82	0.38	0.00	8228
2026-10-28	PRTA	9.1	0.32	0.00	9296
2026-10-29	PRTA	8.87	0.32	0.00	9328
2026-10-30	PRTA	8.48	0.32	0.00	9399
2026-11-02	PRTA	8.3	0.32	0.00	9355
2026-11-03	PRTA	8.21	0.32	0.00	9353
2026-11-04	PRTA	8.4	0.32	0.00	9351
2026-11-05	PRTA	7.91	0.32	999.99	9352
2026-11-06	PRTA	7.98	0.32	0.01	9352
2026-11-09	PRTA	8.78	0.32	0.02	9432
2026-11-10	PRTA	8.56	0.32	7.00	9383
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	PRTA	8.44	43.3	-	0.65
2026-10-13	PRTA	8.37	43.3	-	0.65
2026-10-14	PRTA	8.38	43.3	-	0.65
2026-10-15	PRTA	8.51	43.3	-	0.65
2026-10-16	PRTA	8.35	55.2	-	0.64
2026-10-19	PRTA	8.49	55.2	-	0.64
2026-10-20	PRTA	8.49	55.2	-	0.64
2026-10-21	PRTA	8.51	55.2	-	0.64
2026-10-22	PRTA	8.25	55.2	-	0.64
2026-10-23	PRTA	8.20	55.2	-	0.64
2026-10-26	PRTA	8.40	55.2	-	0.64
2026-10-27	PRTA	8.82	55.2	-	0.64
2026-10-28	PRTA	9.12	55.2	-	0.64
2026-10-29	PRTA	8.88	55.2	-	0.64
2026-10-30	PRTA	8.49	55.2	-	0.64
2026-11-02	PRTA	8.30	55.2	-	0.64
2026-11-03	PRTA	8.23	55.2	-	0.64
2026-11-04	PRTA	8.40	55.2	-	0.64
2026-11-05	PRTA	7.90	55.2	-	0.64
2026-11-06	PRTA	7.99	55.2	-	0.64
2026-11-09	PRTA	8.77	55.2	-	0.64
2026-11-10	PRTA	8.57	55.2	-	0.64
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	PRTA	18.81	-0.58	18.11
2026-10-13	PRTA	18.81	-0.58	18.11
2026-10-14	PRTA	18.81	-0.58	18.11
2026-10-15	PRTA	18.15	-0.58	18.20
2026-10-16	PRTA	20.29	-0.58	18.20
2026-10-19	PRTA	20.29	-1.37	18.24
2026-10-20	PRTA	19.94	-1.37	18.24
2026-10-21	PRTA	19.94	-1.37	18.24
2026-10-22	PRTA	19.94	-1.37	18.24
2026-10-23	PRTA	19.94	-1.37	18.24
2026-10-26	PRTA	19.94	-1.47	18.24
2026-10-27	PRTA	22.92	-1.47	18.08
2026-10-28	PRTA	22.92	-1.47	18.08
2026-10-29	PRTA	22.92	-1.47	18.08
2026-10-30	PRTA	22.92	-1.47	18.08
2026-11-02	PRTA	22.92	-1.45	18.08
2026-11-03	PRTA	22.92	-1.45	18.08
2026-11-05	PRTA	22.92	-1.45	18.08
2026-11-06	PRTA	22.92	-1.45	18.08
2026-11-09	PRTA	22.91	-2.31	18.08
2026-11-10	PRTA	25.82	-2.31	18.08
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.32

Avg. EPS Est. Current Quarter

-0.3

Avg. EPS Est. Next Quarter

0.52

Insider Transactions

25.82

Institutional Transactions

-2.31

Beta

-0.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

89.2

Max Drawdown 5-Year %

-94.2

Target Price

21.4

P/E

Forward P/E

PEG

P/S

8.34

P/B

1.63

P/Free Cash Flow

EPS

-0.47

Average EPS Est. Cur. Y

0.64

EPS Next Y. (Est.)

-1.32

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-45.43

Relative Volume

0.84

Return on Equity vs Sector %

-35.2

Return on Equity vs Industry %

-15.5

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

0.64

EBIT Estimation

◆ PRTA Healthcare

$8.56

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

11/25

Volume

7/15

Valuation

12/20

TP/AR

1/10

Options

5/10

RSI

51.4

Range 1M

52.2%

Sup Dist

5.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

2/25

Growth

18/30

Estimates

0/20

Inst/Vol

0/15

Options

7/10

EPS Yr

99.5%

EPS NY

-4082.3%

52W%

20.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +150% upside

Quality

7/30

Valuation

16/30

Growth

13/25

Stability

8/10

LT Trend

1/5

Upside

+150%

Quality

PRTA — P/E HistoricalBiotechnology

Prothena Corporation plc

Sector: Healthcare

Industry: Biotechnology

Employees: 67

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

PRTA

Latest News

—

Caricamento notizie per PRTA…

stock quote shares PRTA -Prothena Corporation plc Stock Price stock today

news today PRTA -Prothena Corporation plc stock forecast ,stock prediction 2023 2024 2025

marketwatch PRTA -Prothena Corporation plc yahoo finance google finance

stock history PRTA -Prothena Corporation plc invest stock market

stock prices PRTA premarket after hours

ticker PRTA fair value insiders trading

PRTA -Prothena Corporation plc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PRTA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y